Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2020

Date : 08/27/2019 @ 8:16PM
Source : PR Newswire (US)
Stock : Global Cord Blood Corporation (CO)
Quote : 4.5373  0.0073 (0.16%) @ 6:35PM

Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2020

Global Cord Blood (NYSE:CO)
Historical Stock Chart

3 Months : From Aug 2019 to Nov 2019

Click Here for more Global Cord Blood Charts.

1Q20 Added 20,815 New Subscribers
Revenues Up 16.9% YoY to RMB273.4 Million ($39.8 Million)                                  
Gross Profit Up 19.4% YoY to RMB227.6 million ($33.2 million)
Operating Income Up 17.8% YoY to RMB112.4 Million ($16.4 Million)
Non-GAAP Operating Income Up 15.0% YoY to RMB124.8 Million ($18.2 Million)
Conference Call to be Held on August 28, 2019, at 8:00 a.m. ET

HONG KONG, Aug. 27, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2020 ended June 30, 2019.

First Quarter of Fiscal 2020 Highlights

  • Revenues increased by 16.9% year-over-year ("YoY") to RMB273.4 million ($39.8 million).
  • New subscribers and accumulated subscriber base were 20,815 and 770,699[1], respectively.
  • Gross profit increased by 19.4% YoY to RMB227.6 million ($33.2 million). Gross margin improved to 83.3% from 81.5% in the prior year period.
  • Operating income increased by 17.8% YoY to RMB112.4 million ($16.4 million).
  • Operating income before depreciation and amortization[2] ("non-GAAP operating income") increased by 15.0% YoY to RMB124.8 million ($18.2 million).
  • Net income attributable to the Company's shareholders increased significantly by 47.3% YoY to RMB108.3 million ($15.8 million) as a result of improved operating income and an increase in fair value of equity securities ("mark-to-market gains") of RMB10.0 million ($1.5 million) in the first quarter.

"During the first quarter of fiscal 2020, even though macro-economic uncertainty continued to pressure consumer spending on preventive healthcare services, we managed to record 20,815 new subscribers, in line with our expectations," said Ms. Ting Zheng, Chairperson and Chief Executive Officer of GCBC. "As we step into a more economically volatile fiscal year, we will remain alert to the market changes as well as any potential developments in the regulatory regime governing the cord blood banking industry in China. We will strive to expand service offerings and may mitigate business concentration risk through acquisitions in addition to increasing our penetration and business expansion."

Summary – First Quarter Ended June 30, 2018 and 2019






Three Months Ended June 30,



2018


2019

(in thousands)


RMB


RMB



US$

Revenues


233,821


273,375



39,822

Gross Profit


190,663


227,626



33,158

Operating Income[3]


95,442


112,386



16,371

Change in Fair Value of Equity Securities


(9,321)


9,979



1,454

Net Income Attributable to the Company's
  Shareholders


73,542


108,344



15,783

Earnings per Ordinary Share (RMB/US$)
 – Basic


0.61


0.89



0.13

 – Diluted


0.61


0.89



0.13









Revenue Breakdown (%)








Processing Fees and Other Services


61.3%


61.3%




Storage Fees


38.7%


38.7%












New Subscribers (persons)


20,601


20,815




Total Accumulated Subscribers (persons)


682,081


770,699[1]












 

 

Summary – Selected Cash Flow Statement Items










Three Months Ended June 30,



2018


2019

(in thousands)


RMB


RMB


US$

Net cash provided by operating activities


175,317


169,756


24,728

Net cash used in investing activities


(7,126)


(6,625)


(965)

Net cash provided by financing activities


-


-


-

 

First Quarter of Fiscal 2020 Financial Results

REVENUES. Revenues increased by 16.9% to RMB273.4 million ($39.8 million) in the first quarter of fiscal 2020. The increase was driven by the implementation of new processing fee since April 2019 and the enlarged client base.

Despite the impact from the processing fee price hike, the new subscriber number still reached the Company's target level. As a result, revenues generated from processing fees and other services in the reporting quarter increased by 16.8 %YoY to RMB167.5 million ($24.4 million).

As the accumulated subscriber base grew to 770,699[1] by the end of June 2019, revenues generated from storage fees increased by 17.1% YoY to RMB105.9 million ($15.4 million) in the reporting quarter. Storage fee revenues accounted for 38.7% of total revenues, which was the same as in the previous year period.

GROSS PROFIT. Gross profit for the reporting quarter increased by 19.4% YoY to RMB227.6 million ($33.2 million). Gross margin improved to 83.3% from 81.5% in the prior year period. Such margin improvement was mainly due to the increase in processing fee which exceeded the increase in direct costs such as raw materials and collection costs.

OPERATING INCOME. As the increase in gross profit was partially offset by the increase in operating expenses, operating income for the reporting quarter increased by 17.8% YoY to RMB112.4 million ($16.4 million). Operating margin increased to 41.1% in the reporting quarter from 40.8% in the prior year period. Depreciation and amortization expenses related to properties, plant and equipment and intangible assets for the first quarter were RMB12.4 million ($1.8 million), compared to RMB13.1 million in the prior year period. Non-GAAP operating income[2] improved by 15.0% YoY to RMB124.8 million ($18.2 million).

Sales and Marketing Expenses. Sales and marketing expenses for the reporting quarter amounted to RMB60.6 million ($8.8 million) compared to RMB51.4 million in the prior year period. Processing fee upward adjustment combined with lackluster consumer spending required more intense sales and marketing efforts to achieve the Company's conversion targets. The Company also stepped up its sales force recruitment effort with more hiring. Sales and marketing expenses as a percentage of revenues were 22.2%, compared to 22.0% in the prior year period.

General and Administrative Expenses. General and administrative expenses for the reporting quarter amounted to RMB49.9 million ($7.3 million), compared to RMB41.0 million in the prior year period. Higher administrative expenses, staff costs, and legal and professional fees all contributed to the increase in general and administrative expenses. General and administrative expenses as a percentage of revenues was 18.3%, compared to 17.5% of the prior year period.

OTHER INCOME AND EXPENSES.

Change in Fair Value of Equity Securities. In the first quarter, the Company recognized an increase in fair value of equity securities, or "mark-to-market gains", of RMB10.0 million ($1.5 million) while a decrease in fair value of equity securities of RMB9.3 million was recorded in the prior year period. Such changes were mainly attributable to the investments in Cordlife Group Limited ("Cordlife").

NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. As a result of the increase in operating income and the increase in fair value of equity securities, income before income tax for the first quarter increased by 42.1% YoY to RMB129.4 million ($18.9 million). Income tax expense for the reporting quarter was RMB19.5 million ($2.8 million). Net income attributable to the Company's shareholders for the reporting quarter increased by 47.3% YoY to RMB108.3 million ($15.8 million). Net margin for the first quarter improved by 8 percentage points to 39.6%.

EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the first quarter fiscal 2020 was RMB0.89 ($0.13).

Recent Developments

  • On June 4, 2019, the board of directors of the Company (the "Board") received a non-binding proposal letter from Cordlife, a company listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX"), pursuant to which Cordlife proposes to combine the businesses of Cordlife and the Company, by way of a statutory merger. According to the letter, Cordlife would issue approximately 2,497.9 million ordinary shares at an issue price of SGD0.5 per ordinary share in exchange for all of the outstanding ordinary shares of the Company at $7.50 per ordinary share. Upon completion of the proposed transaction, the Company's ordinary shares will be delisted from the New York Stock Exchange and the Cordlife ordinary shares will continue to trade on SGX. On June 5, 2019, the Board formed a special committee of independent directors (the "Special Committee") who are not affiliated with Cordlife to evaluate such proposal. The Special Committee intends to retain advisors, including an independent financial advisor and U.S. and Cayman Islands legal counsels, to assist it in its work.
  • The Company cautions its shareholders and others considering trading its ordinary shares that no decisions have been made with respect to the Company's response to the proposed transaction. The proposed transaction is still subject to various conditions, including but not limited to, completion of due diligence, parties entering into definitive agreement, and/or each of Cordlife and the Company obtaining its relevant regulatory and shareholders approval. In addition, litigation has been filed in the Cayman Islands challenging the proposed transaction. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated.

 

[1] During the three months ended June 30, 2019, 20,815 new subscribers were recruited. The Company reclassified 389 private cord blood units as donated cord blood units during the three months ended June 30, 2019 after the Company determined that the recoverability of these prior private cord blood banking subscribers was remote. Therefore, the Company terminated their subscription services according to the subscription contracts and these units are being treated as if they were donated cord blood units and will be part of the Company's non-current inventories. Hence, the net accumulated subscriber base was 770,699 as of June 30, 2019.

[2] See exhibit 3 to this press release for a reconciliation of non-GAAP operating income to exclude the non-cash items related to the depreciation and amortization expenses to the comparable financial measure prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").

[3] The reported operating income for the three months ended June 30, 2018 and 2019 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB13.1 million and RMB12.4 million ($1.8 million), respectively.

 

Conference Call

The Company will host a conference call at 8:00 a.m. ET on Wednesday, August 28, 2019 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at http://ir.globalcordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for seven days at the same URL above. Listeners can also access the call by dialing 1-855-824-5644 or 1-646-722-4977 for US callers, or +852-3027-6500 for Hong Kong callers, access code: 62299537#.

Use of Non-GAAP Financial Measures

GAAP results for the three months ended June 30, 2019 include non-cash items related to the depreciation and amortization expenses. To supplement the Company's unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company's management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company's historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.

About Global Cord Blood Corporation

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today.  Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.  For more information, please visit our website at http://www.globalcordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, the presence of a new majority shareholder, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions; the non-binding proposal letter from Cordlife and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the period ending June 30, 2019 were made at the noon buying rate of RMB6.8650 to $1.00 on June 28, 2019 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. Global Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

 

 

EXHIBIT 1

GLOBAL CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and June 30, 2019



March 31,


June 30,


2019


2019


RMB


RMB


US$


(in thousands except share data)

ASSETS






Current assets






Cash and cash equivalents

4,997,861


5,162,037


751,936

Accounts receivable, less allowance for doubtful






  accounts (March 31, 2019: RMB89,634;            






  June 30, 2019: RMB96,587 (US$14,069))

96,923


96,294


14,027

Inventories

27,612


25,352


3,694

Prepaid expenses and other receivables

25,532


21,615


3,149

Total current assets

5,147,928


5,305,298


772,806

Property, plant and equipment, net

545,340


540,986


78,803

Operating lease right-of-use assets[4]

-


6,365


927

Non-current deposits

236,719


242,556


35,332

Non-current accounts receivable, less allowance






  for doubtful accounts (March 31, 2019: RMB74,800;






  June 30, 2019: RMB74,089 (US$10,792))

104,857


111,417


16,230

Inventories

77,194


78,529


11,439

Intangible assets, net

97,444


96,289


14,026

Investment in equity securities at fair value

107,362


120,443


17,545

Other equity investment

189,129


189,129


27,550

Deferred tax assets

44,981


47,473


6,915

Total assets

6,550,954


6,738,485


981,573







LIABILITIES






Current liabilities






Accounts payable

33,566


28,522


4,155

Accrued expenses and other payables

79,977


95,362


13,891

Operating lease liabilities[4]

-


2,174


317

Deferred revenue

461,986


444,402


64,734

Income tax payable

20,113


23,728


3,456

Total current liabilities

595,642


594,188


86,553

Non-current deferred revenue

2,108,442


2,161,478


314,855

Non-current operating lease liabilities[4]

-


3,491


509

Other non-current liabilities

404,482


417,107


60,759

Deferred tax liabilities

19,626


19,178


2,794

Total liabilities

3,128,192


3,195,442


465,470







EQUITY






Shareholders' equity of Global Cord Blood
Corporation






Ordinary shares






- US$0.0001 par value, 250,000,000 shares
authorized, 121,687,974 and 121,551,075 shares issued and outstanding
as of March 31 and June 30, 2019, respectively

83


83


12

Additional paid-in capital

2,101,582


2,101,582


306,129

Treasury stock, at cost (March 31 and June 30,






  2019: 136,899 shares, respectively)

(2,815)


(2,815)


(410)

Accumulated other comprehensive losses

(88,738)


(78,385)


(11,418)

Retained earnings

1,407,223


1,515,567


220,768

Total equity attributable to Global Cord Blood






  Corporation

3,417,335


3,536,032


515,081

Non-controlling interests

5,427


7,011


1,022

Total equity

3,422,762


3,543,043


516,103

Total liabilities and equity

6,550,954


6,738,485


981,573







[4] During the reporting quarter, the Company adopted Accounting Standards Update Topic 842 using a modified retrospective transition
approach which resulted in the recognition of right-of-use assets and lease liabilities for operating leases as of April 1, 2019 of
approximately RMB6.9 million ($1.0 million) and RMB5.8 million ($0.8 million), respectively.

 

 

EXHIBIT 2

GLOBAL CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months ended June 30, 2018 and 2019




Three months ended June 30,



2018


2019



RMB


RMB


US$



           (in thousands except per share data)








Revenues


233,821


273,375


39,822

Direct costs


(43,158)


(45,749)


(6,664)

Gross profit


190,663


227,626


33,158

Operating expenses







Research and development


(2,791)


(4,701)


(685)

Sales and marketing


(51,415)


(60,637)


(8,833)

General and administrative


(41,015)


(49,902)


(7,269)

Total operating expenses


(95,221)


(115,240)


(16,787)

Operating income


95,442


112,386


16,371

Other (expenses)/income, net







Interest income


5,698


6,220


906

Foreign currency exchange losses


(26)


(28)


(4)

Change in fair value of equity securities   


(9,321)


9,979


1,454

Dividend income


-


507


74

Others


(759)


340


50

Total other (expenses)/income, net


(4,408)


17,018


2,480

Income before income tax 


91,034


129,404


18,851

Income tax expense


(16,524)


(19,476)


(2,837)

Net income


74,510


109,928


16,014

Net income attributable to non-controlling interests 


(968)


(1,584)


(231)

Net income attributable to Global Cord







  Blood Corporation's shareholders


73,542


108,344


15,783








Earnings per share:







Attributable to ordinary shares







-   Basic


0.61


0.89


0.13

-   Diluted


0.61


0.89


0.13















Other comprehensive income,







   net of nil income taxes







- Foreign currency translation adjustments


22,880


10,353


1,508








Comprehensive income


97,390


120,281


17,522








Comprehensive income attributable to







  non-controlling interests


(968)


(1,584)


(231)

Comprehensive income attributable to







Global Cord Blood Corporation's shareholders


96,422


118,697


17,291

 

 

EXHIBIT 3

GLOBAL CORD BLOOD CORPORATION

RECONCILIATION OF NON-GAAP OPERATING INCOME

For the Three Months Ended June 30, 2018 and 2019



Three months ended June 30,


2018


2019


RMB


RMB


US$




(in thousands)









GAAP amount of operating income

95,442


112,386


16,371







Depreciation and amortization expenses[5]

13,145


12,445


1,813







Non-GAAP operating income

108,587


124,831


18,184







[5] Depreciation and amortization expenses related to property, plant and equipment and intangible assets respectively.


 

 

Cision View original content:http://www.prnewswire.com/news-releases/global-cord-blood-corporation-reports-financial-results-for-the-first-quarter-of-fiscal-2020-300907434.html

SOURCE Global Cord Blood Corporation

Copyright 2019 PR Newswire

Latest CO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.